Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Genital Warts

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Genital Warts. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-004465-24 Sponsor Protocol Number: EXP-1167 Start Date*: 2015-02-18
    Sponsor Name:LEO Pharma A/S
    Full Title: Safety and efficacy of repeat use of Picato® 0.05% in the treatment of anogenital warts
    Medical condition: Anogenital warts
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059313 Anogenital warts PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001443-52 Sponsor Protocol Number: LLB-2019-02 Start Date*: 2019-11-13
    Sponsor Name:LABO'LIFE Belgium sprl
    Full Title: Randomized study to evaluate 2LVERU® JUNIOR and 2LVERU® efficacy on the treatment of warts. Protocol EVAsION
    Medical condition: Non genital warts infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035150 Planar warts LLT
    20.0 100000004864 10035158 Plantar warts LLT
    20.0 100000004864 10047828 Warts LLT
    21.1 100000004864 10010115 Common warts LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005553-13 Sponsor Protocol Number: CLS001-CO-PR-011 Start Date*: 2016-05-11
    Sponsor Name:Cutanea Life Sciences
    Full Title: A PHASE 2, RANDOMIZED, VEHICLE-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EXPLORE THE PHARMACODYNAMICS, SAFETY AND EFFICACY OF TOPICAL OMIGANAN IN PATIENTS WITH EXTERNAL GENITAL WARTS
    Medical condition: Patients with external genital warts
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10018182 Genital warts LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000162-40 Sponsor Protocol Number: IFN 001 Start Date*: 2005-09-06
    Sponsor Name:Helix Product Development (Ireland) Limited
    Full Title: Treatment of genital warts with Interferon alpha-2b Cream: a randomized, double blind, placebo-controlled study
    Medical condition: Condylomata acuminata (genital warts)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004893-42 Sponsor Protocol Number: 1.0 Start Date*: 2008-10-15
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für dermatologie
    Full Title:
    Medical condition: Condyloma accuminata, Vulvar Intraepithelial Neoplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047762 Vulval neoplasms benign HLT
    9.1 10010291 Condyloma acuminatum LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002455-20 Sponsor Protocol Number: P150957 Start Date*: 2016-11-18
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Efficacy study of the quadrivalent Human Papilloma Virus (HPV) vaccine to prevent recurrence of External Genital Warts (EGW) in patients who were cured in the first place
    Medical condition: Patients whose EGW have just disappeared after initial success of classic treatment
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059313 Anogenital warts PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004007-13 Sponsor Protocol Number: NCT-2010-1090 Start Date*: 2013-09-06
    Sponsor Name:Deutsches Krebsforschungszentrum (DKFZ
    Full Title: A randomized, placebo-controlled, phase IIIb HPV vaccination trial with Gardasil® in patients with recurrent condylomata acuminata
    Medical condition: Patients with recurrrent external condylomata acuminata located at the following genital regions: labia minora and majora, introitus vaginae, clitoris, prepuce, glans penis, coronal sulcus and fren...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016515 10010295 Condylomata acuminatum LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000870-39 Sponsor Protocol Number: CHDR1607 Start Date*: 2017-08-21
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, vehicle-controlled, double-blind study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide i...
    Medical condition: HPV-induced genital lesions of immunocompromised and immunocompetent patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016515 10018182 Genital warts LLT
    20.0 100000024086 10064455 HSIL LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003688-39 Sponsor Protocol Number: CLS003-CO-PR-002 Start Date*: 2014-11-26
    Sponsor Name:Cutanea Life Sciences
    Full Title: A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in C...
    Medical condition: Patients with at least two warts who are otherwise healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10010115 Common warts LLT
    17.1 100000004864 10035158 Plantar warts LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002951-14 Sponsor Protocol Number: 12/0357 Start Date*: 2016-06-17
    Sponsor Name:University College London
    Full Title: Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccinat...
    Medical condition: Anogenital warts
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059313 Anogenital warts PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018182 Genital warts LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005717-23 Sponsor Protocol Number: V501-018-00 Start Date*: 2015-12-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL™ at 9-18 Years of Age
    Medical condition: HPV
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-002945-10 Sponsor Protocol Number: V501-020 Start Date*: 2005-02-18
    Sponsor Name:Suomen MSD OY
    Full Title: A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the I...
    Medical condition: Prevention of Human Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-006002-27 Sponsor Protocol Number: CHUBX2011/18 Start Date*: 2012-07-31
    Sponsor Name:CHU de Bordeaux
    Full Title: Multicentre trial evaluating the immunogenicity of HPV vaccination in girls on immunosuppressive therapy.
    Medical condition: Infection by HPV 6, 11, 16, 18
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004654-19 Sponsor Protocol Number: 1526-IMIQ Start Date*: 2005-04-20
    Sponsor Name:3M ITALIA
    Full Title: Multicenter, randomized, double-blind, vehicle-controlled study comparing recurrence rate following imiquimod 5% cream or vehicle 3 times per week for 4 weeks prior to ablative therapy in subjects ...
    Medical condition: External ano-genital warts
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033724 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004933-14 Sponsor Protocol Number: V502-003-01 Start Date*: 2006-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 45, 52, and 58.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011617-25 Sponsor Protocol Number: V503-002 Start Date*: 2009-10-16
    Sponsor Name:MSD Finland Oy
    Full Title: A Study to Demonstrate Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents an...
    Medical condition: Cervical Cancer
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-006761-32 Sponsor Protocol Number: A 091152 Start Date*: 2008-04-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: Vulval intraepithelial neoplasia: immune responses to human papillpmavirus.
    Medical condition: Vulval intraepithelial neoplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056574 Vulval intraepithelial neoplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-008605-22 Sponsor Protocol Number: 1.0 Start Date*: 2009-03-13
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Dermatologie
    Full Title: Determination of the human papillomavirus (HPV)-specific antibody status in oral fluids of individuals vaccinated with a quadrivalent HPV vaccine
    Medical condition: Healthy women aged 18-26
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065136 Human papilloma virus exposure LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002931-16 Sponsor Protocol Number: V501-122 Start Date*: 2018-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese men
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004581-16 Sponsor Protocol Number: V501-030 Start Date*: 2015-04-02
    Sponsor Name:Merck Sharp & Dohme (China) Ltd.
    Full Title: An Immunogenicity and Safety Study of GARDASIL™ in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years
    Medical condition: Prevention of HPV types 6, 11, 16 and 18 related cervical cancer, vulvar, vaginal pre-cancers, low-grade, pre-cancerous lesions, and genital warts in Chinese female subjects aged 9 to 45 years and ...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:28:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA